<DOC>
	<DOCNO>NCT00005581</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know regimen chemotherapy effective breast cancer . PURPOSE : Randomized phase III trial compare effectiveness two regimen combination chemotherapy treat woman stage II stage III breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Women With Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall survival disease free survival adjuvant chemotherapy epirubicin plus paclitaxel versus cyclophosphamide , epirubicin , fluorouracil woman stage IIA , IIB , III breast cancer . II . Compare quality life woman treatment regimen . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm within 35 day surgery . Arm I : Patients receive epirubicin IV follow paclitaxel IV 3 hour day 1 . Treatment repeat every 21 day 4 course . Arm II : Patients receive cyclophosphamide IV , epirubicin IV , fluorouracil IV day 1 . Treatment repeat every 21 day 6 course . Treatment continue absence disease progression unacceptable toxicity . Patients postmenopausal , premenopausal hormone receptor positive , receive tamoxifen orally day 5 year start day 1 . Patients receive radiotherapy residual breast 4 course chemotherapy . Quality life assess . Patients follow every 3 month 3 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : Approximately 1,000 patient accrue study 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIA , IIB , III breast cancer treat radical surgery ( e.g. , mastectomy , quadrantectomy , tumorectomy ) axillary lymph node dissection Positive axillary lymph nod No 9 metastatic lymph nod No distant metastasis local locoregional disease No 5 week surgery begin study Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 70 Sex : Female Menopausal status : Not specify Performance status : ECOG 0 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Transaminases , alkaline phosphatase , gamma glutamyltransferase great 1.5 time upper limit normal Renal : Not specify Cardiovascular : No heart disease precludes use anthracyclines ( i.e. , myocardial infarction , uncontrolled angina pectoris , uncontrolled arrhythmia , valve disease ) Other : No concurrent pathology precludes use antineoplastic drug No mental retardation psychiatric disease precludes study No current prior malignancy within past 10 year except squamous basal cell skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : No prior antineoplastic hormonal therapy Radiotherapy : No postoperative radiotherapy except residual breast Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>